格隆汇9月4日丨恒瑞医药(600276.SH)公布，子公司瑞石生物医药有限公司收到国家药品监督管理局核 准签发关于RSS0393软膏的《药物临床试验批准通知书》，将于近期开展临床试验。RSS0393软膏是公 司自主研发的含PDE4小分子抑制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活性，缓解组织损伤 和炎症。 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of RSS0393 ointment, which will commence shortly [1] Group 1: Product Development - RSS0393 ointment is a self-developed product by Heng Rui Medicine, containing a PDE4 small molecule inhibitor [1] - The ointment is designed to alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells upon application [1]

Group 1 - The core point of the article is that Heng Rui Medicine (600276.SH) announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of RSS0393 ointment [1] - RSS0393 ointment is a self-developed product by the company, which contains a PDE4 small molecule inhibitor that can alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells [1]

智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司瑞石生物医药有限公司收到国家 药品监督管理局(简称"国家药监局")核准签发关于RSS0393软膏的《药物临床试验批准通知书》，将于 近期开展临床试验。 SS0393软膏是公司自主研发的含PDE4小分子抑制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活 性，缓解组织损伤和炎症。 ...

恒瑞医药9月4日公告，子公司瑞石生物医药有限公司收到国家药监局核准签发关于RSS0393软膏的《药 物临床试验批准通知书》，将于近期开展临床试验。RSS0393软膏是公司自主研发的含PDE4小分子抑 制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活性，缓解组织损伤和炎症。 ...